Spectral AI Reports Strong Q1 2025 Results

Spectral Ai, Inc. Class A ( (MDAI) ) has released its Q1 earnings. Here is a breakdown of the information Spectral Ai, Inc. Class A presented to its investors.

Spectral AI, Inc., based in Dallas, is a predictive artificial intelligence company specializing in medical diagnostics, particularly in wound care, with its flagship DeepView® System designed to enhance treatment decisions for burn injuries.

In its first quarter of 2025, Spectral AI reported significant financial and strategic progress, with a notable increase in research and development revenue and a strengthened capital structure. The company is on track with its strategic objectives, including a planned De Novo submission to the FDA.

Key financial highlights include a 6% rise in research and development revenue to $6.7 million, an improved gross margin of 47.2%, and a turnaround to a net income of $2.9 million from a previous net loss. The company also completed a substantial debt and equity financing, bolstering its cash reserves to $14.1 million, which supports its upcoming product commercialization efforts.

Strategically, Spectral AI completed its Burn Validation Study, one of the largest of its kind in the U.S., demonstrating the efficacy of its DeepView® System. The study involved 164 patients and showcased the system’s superior predictive capabilities compared to traditional clinical judgment.

Looking ahead, Spectral AI remains focused on its FDA submission and commercialization plans, maintaining a revenue guidance of approximately $21.5 million for the full year 2025, excluding potential contributions from its DeepView® System sales.